MARKET

HMTXF

HMTXF

Hemostemix
OTCMQB
0.055
NaN%
Closed 10:02 08/20 EDT
OPEN
--
PREV CLOSE
0.040
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.092
52 WEEK LOW
0.038
MARKET CAP
11.23M
P/E (TTM)
-3.4465
1D
5D
1M
3M
1Y
5Y
1D
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Newsfile · 23h ago
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Newsfile · 08/12 12:23
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Newsfile · 07/30 21:57
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Newsfile · 07/28 16:14
Hemostemix Grants Stock Options
Newsfile · 07/22 20:50
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Newsfile · 07/08 14:08
Hemostemix Closes $360,000 First Tranche of Private Placement
Newsfile · 06/26 12:47
Hemostemix' $1,000,000 Private Placement and Update
Newsfile · 06/17 21:22
More
About HMTXF
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Webull offers Hemostemix Inc stock information, including OTCMQB: HMTXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HMTXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HMTXF stock methods without spending real money on the virtual paper trading platform.